J. Myllymäki

Vascular diseases and their risk factors in IgA nephropathy.

H. Helin, J. Mustonen, A. Pasternack, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Uric acid correlates with the severity of histopathological parameters in IgA nephropathy.

H. Helin, J. Mustonen, A. Pasternack, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Severity of tubulointerstitial inflammation and prognosis in immunoglobulin A nephropathy.

H. Helin, J. Mustonen, A. Pasternack, 2007, Kidney international.

Small bowel cyclooxygenase 2 (COX-2) expression in patients with IgA nephropathy.

J. Mustonen, P. Collin, M. Hurme, 2005, Kidney international.

Combination Therapy of Intravenous Maxacalcitol and Percutaneous Ethanol Injection Therapy Lowers Serum Parathyroid Hormone Level and Calcium × Phosphorus Product in Secondary Hyperparathyroidism

T. Fujita, T. Fujita, M. Matsushita, 2005, Nephron Clinical Practice.

Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency.

J. Mustonen, I. Pörsti, O. Niemelä, 2009, American journal of hypertension.

IgM nephropathy: clinical picture and long-term prognosis.

Heikki Helin, Jukka Mustonen, Heikki Saha, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Clinical features and long term prognosis in two forms of mesangial glomerulonephritis, IgA nephropathy and IgM nephropathy

J. Myllymäki, 2008 .

High Serum C3 Predicts Poor Outcome in IgM Nephropathy

H. Helin, J. Mustonen, A. Pasternack, 2005, Nephron Clinical Practice.

Moderate hyperuricaemia ameliorated kidney damage in a low‐renin model of experimental renal insufficiency

T. Paavonen, I. Tikkanen, J. Mustonen, 2022, Basic & clinical pharmacology & toxicology.